Skip to content

Clinical application of PSMA-targeted radionuclide fluorescent bimodal probe 68Ga/18F-P3 in preoperative imaging and intraoperative navigation of prostate cancer

Clinical application of PSMA-targeted radionuclide fluorescent bimodal probe 68Ga/18F-P3 in preoperative imaging and intraoperative navigation of prostate cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400083878
Enrollment
Unknown
Registered
2024-05-06
Start date
2024-05-07
Completion date
Unknown
Last updated
2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prostate cancer

Interventions

experimental group:Utilization of 68Ga/18F-P3 for preoperative imaging and intraoperative navigation

Sponsors

Peking University First Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: a) patients with prostate cancer who need surgical treatment. b) confirmed by traditional imaging (bone imaging, CT or MRI) or PET/CT that there was no non-regional lymph node metastasis, bone metastasis or other site metastasis (such as visceral metastasis), namely M0. c) patients with pelvic lymph node metastasis (N1) are allowed to enter the group. d) 18 years old = age = 80 years old. e) through preoperative communication, the patients and their families indicated that they were fully aware of the disease and the choice of treatment and signed the informed consent form and informed choice notice.

Exclusion criteria

Exclusion criteria: a) patients who do not sign informed consent and cannot cooperate with the study. b) patients who cannot tolerate PET/CT or RLRP. c) have previously received any of the following treatments for prostate cancer: ? systemic therapy, including but not limited to: ADT therapy for more than 2 months, traditional endocrine therapy for more than 2 months, new endocrine therapy, chemotherapy, immunotherapy, targeted therapy. ? local treatment, including but not limited to pelvic radiotherapy and surgery for prostate cancer. D) malignant tumors other than prostate cancer in the past 5 years or at the same time

Design outcomes

Primary

MeasureTime frame
Consistency between intraoperative fluoroscopic pelvic lymph nodes (positive or negative) and histopathological findings (benign or malignant);

Secondary

MeasureTime frame
positive surgical margin;Consistency between intraoperative fluoroscopic pelvic lymph nodes (positive or negative) and histopathological findings (benign or malignant);

Countries

China

Contacts

Public ContactXuesong Li

Peking University First Hospital

pineneedle@sina.com+86 10 8357 2418

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026